Invitae

Invitae Share Buybacks

Delisted

The Share Buybacks of Invitae (NVTAQ) as of Oct 5, 2026 is 23.77 M USD. In the previous year, Share Buybacks was 284.20 M USD — a change of -91.64% (lower).

Share Buybacks

23.77 MUSD

YoY

-91.64%

Last updated:

Share Buybacks of Invitae is 2026 23.77 M USD. Share Buybacks of Invitae was 2025 284.20 M USD. It decreases by -91.64% lower compared to the previous year.

The Invitae Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2014
209,000.00 USD
Jan 1, 2015
107.41 M USD
Jan 1, 2016
50.24 M USD
Jan 1, 2017
74.62 M USD
Jan 1, 2018
17.51 M USD
Jan 1, 2019
9.47 M USD
Jan 1, 2020
284.20 M USD
Jan 1, 2021
23.77 M USD
The Invitae Share Buybacks history
YEARShare BuybacksYoY
23.77 MUSD-91.64%
284.20 MUSD+2,901.09%
9.47 MUSD-45.92%
17.51 MUSD-76.53%
74.62 MUSD+48.54%
50.24 MUSD-53.23%
107.41 MUSD+51,291.39%
209,000.00USD—
Access this data via the Eulerpool API

Invitae Stock analysis

What does Invitae do? Invitae Corp is a US-based company specialized in providing genetic tests for the diagnosis, treatment, and prevention of diseases. It was founded in 2010 and is headquartered in San Francisco, California. The company's goal is to lower the cost of genetic testing and increase accessibility for patients through automation and sample pooling methods. Invitae has received significant funding and has expanded its capital through multiple rounds of investments from venture capital firms, totaling nearly half a billion dollars. Its business model focuses on offering genetic tests to a wide range of patient groups, streamlining the testing processes through automation and software optimization. Invitae serves consumers directly, as well as medical professionals, hospitals, health centers, laboratories, and health insurance companies. The company aims to improve disease diagnosis and early detection while promoting long-term patient health. Invitae has broadened its capabilities through strategic acquisitions and partnerships, consolidating genetic data on a single platform. It offers a diverse portfolio of genetic tests for the diagnosis, treatment, and prevention of various diseases, including cancer predisposition, cardiovascular diseases, rare inherited diseases, neurological disorders, and medical genomics. The company also provides genetic counseling and family-oriented diagnosis services, along with an online platform facilitating interactive communication between doctors and patients, enabling the sharing and presentation of genetic information and test results. Invitae is an innovative company that has established itself as a market leader in genetic testing, offering a wide range of products and services facilitated by advanced technologies and data storage solutions. The recent acquisitions and partnerships have expanded Invitae's portfolio, improved its technology platform, and strengthened its position as a provider of high-quality healthcare services, enabling well-informed decision-making for patients and medical professionals. Invitae is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invitae stock

Share Buybacks of Invitae is 23.77 M USD in 2026.

Share Buybacks of Invitae changed from 284.20 M USD to 23.77 M USD, representing a -91.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Share Buybacks Invitae since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's Invitae historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Invitae

All Key Metrics — Invitae